Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMuhammad Furqan
About this trial
The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.
Eligibility criteria
Qualifiers
Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
Age >= 18 years at the time of consent.
ECOG Performance Status of 0-1 within 14 days prior to registration (Appendix A of Protocol).
Histological or cytological confirmed small cell lung carcinoma
Disqualifiers
Prior systemic therapy for extensive stage or recurrent SCLC
Patients with recurrent SCLC, who received chemotherapy or definitive chest radiation in the past for limited-stage SCLC.
Clinically significant active infection requiring systemic therapy
Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
Trial design
Treatments tested in this trial
- Cisplatin
- Carboplatin
- Etoposide
- Durvalumab
- Ceralasertib
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Muhammad Furqan
Lead sponsor
Big Ten Cancer Research Consortium
Sponsor institution
AstraZeneca
Collaborator
Source ClinicalTrials.gov